Results 51 to 60 of about 14,668 (165)

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro

open access: yesBrain, Behavior, & Immunity - Health
Multiple myeloma is a haematological cancer characterised by the accumulation of clonal plasma cells in the bone marrow and is commonly treated with daratumumab, an anti-CD38 monoclonal antibody immunotherapy.
Harrison D. Collier-Bain   +13 more
doaj   +1 more source

Bone recovery after treatment study: Evidence of myeloma bone disease repair and partial microenvironment recovery

open access: yesBritish Journal of Haematology, EarlyView.
Summary Myeloma bone disease (MBD) affects ~90% of myeloma patients, causing pain and reduced quality of life. Current anti‐resorptive treatments retard further destruction but do not repair bone. As new myeloma therapies emerge, understanding their impact on MBD is crucial.
Rebecca E. Andrews   +7 more
wiley   +1 more source

Whole‐genome and transcriptome analysis in relapsed/refractory non‐Hodgkin lymphoma: Results from a multicentre precision oncology cohort

open access: yesBritish Journal of Haematology, EarlyView.
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee   +24 more
wiley   +1 more source

Daratumumab bewährt sich in der Rezidivtherapie

open access: yes, 2018
Die aktualisierte Auswertung der Phase-III-Studie POLLUX untermauert den anhalten-den Benefit von Daratumumab zusätzlich zu Lenalidomid/Dexamethason (Rd) bei Patientien mit rezidiviertem oder refraktärem MM (rrMM): Durch die Daratumumab-Addition werden ...
Katharina Arnheim
core   +1 more source

Daratumumab‐Based Combinational Therapy as Second‐Line Treatment of Relapsed‐Refractory Multiple Myeloma: A Single‐Center Experience

open access: yesCancer Reports
Background Daratumumab represents the first‐in‐class fully humanized monoclonal antibody that targets CD38 for the treatment of relapsed/refractory multiple myeloma (RRMM).
Oscar C. Y. Yang   +7 more
doaj   +1 more source

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

open access: yesJournal of Hematology & Oncology, 2016
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
Larysa Sanchez   +3 more
doaj   +1 more source

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

open access: yesHaematologica, 2020
The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma.
Maria-Victoria Mateos   +18 more
doaj   +1 more source

Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH‐MM‐15 Study

open access: yesCancer Science, EarlyView.
t(11;14)‐positive MM is a clinically distinct subgroup characterized by intermediate prognostic risk, modest response depth, and treatment‐dependent outcomes. ABSTRACT t(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor.
Taku Tsukamoto   +24 more
wiley   +1 more source

Patient and Healthcare Provider Satisfaction With Subcutaneous Versus Intravenous Administration of Daratumumab in Combination With Lenalidomide and Dexamethasone as First‐Line Treatment in Patients With Newly Diagnosed Non‐Transplant Eligible Multiple Myeloma: Final Results of the MYLENE Study

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives The MYLENE non‐interventional study (NIS) aimed to close the gap in real‐world data on the experience and satisfaction with subcutaneous (sc) and intravenous (iv) daratumumab application in patients with newly diagnosed non‐transplant eligible multiple myeloma in Germany.
Eyck von der Heyde   +9 more
wiley   +1 more source

Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine

open access: yesInternational Journal of Infectious Diseases
Objectives: Daratumumab-treated myeloma patients may face increased seasonal influenza risk due to weakened postvaccination immune responses, especially with daratumumab treatment.
Simon B. Gressens   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy